ABOUT
Vir is a science-driven company guided by medical need.
Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Vir is taking a multi-program, multi-platform approach to applying these breakthroughs, including the development of treatments that induce protective and therapeutic immune responses. Vir’s scale and scope, together with leading scientific and management expertise, allow it to perform significant internal R&D, in-license or acquire innovative technology platforms and assets, and fund targeted academic research.
Vir’s initial focus is in three areas of significant unmet need: chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and health-care acquired infections.
The company was founded by Robert Nelsen and ARCH Venture Partners and seeded by ARCH, the Bill & Melinda Gates Foundation, Altitude Life Sciences, and Alta Partners. Additional investors include the SoftBank Vision Fund, Temasek, Baillie Gifford, the Alaska Permanent Fund, and select sovereign wealth funds, private individuals, family offices, and other institutional investors.
Vir is headquartered in San Francisco, California with operations in Portland, Oregon, Boston, Massachusetts, and Bellinzona, Switzerland
Team
The Vir team is comprised of world leaders in immunology, infectious disease, and drug development. Learn more about our executive team, board of directors, and scientific advisors below.
Executive Team
Board of Directors
Scientific Advisors
News
SAN FRANCISCO—Vir Biotechnology, Inc. today announced the appointment of Antonio Lanzavecchia, M.D., as Senior Vice President and Senior Research Fellow, effective immediately. Reporting to Chief Executive Officer George Scangos, Ph.D., Dr. Lanzavecchia will provide scientific leadership for Vir’s technical programs that are designed to transform the care of people with serious infectious diseases.
SAN FRANCISCO—Vir Biotechnology, Inc. today announced the appointment of Herbert W. "Skip" Virgin, M.D., Ph.D., as Executive Vice President of Research and Chief Scientific Officer, effective January 1, 2018. Reporting to CEO George Scangos and joining Vir’s management team, Dr. Virgin will lead the company’s significant and growing R&D programs to transform the care of people with serious infectious diseases.
CAREERS at Vir Bio
Vir is always interested in knowing the best and the brightest talent. If you do not see a role that matches your background we encourage you to email your resume to resumes@vir.bio. This will help us find you if a new need arises that fits your experience.
Contact
VIR BIOTECHNOLOGY, INC.
499 Illinois Suite 500
San Francisco, CA 94158
415-906-4324
email: info@vir.bio